Safety and efficacy of pyronaridine-artesunate paediatric granules in the treatment of uncomplicated malaria in children: insights from randomized clinical trials and a real-world study.
Plasmodium falciparum
Anti-malarial
Granule formulation
Malaria
Paediatric
Pyronaridine–artesunate
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
28 Feb 2024
28 Feb 2024
Historique:
received:
29
09
2023
accepted:
20
02
2024
medline:
29
2
2024
pubmed:
29
2
2024
entrez:
28
2
2024
Statut:
epublish
Résumé
Children are particularly at risk of malaria. This analysis consolidates the clinical data for pyronaridine-artesunate (PA) paediatric granules in children from three randomized clinical trials and a real-world study (CANTAM). An integrated safety analysis of individual patient data from three randomized clinical trials included patients with microscopically-confirmed Plasmodium falciparum, body weight ≥ 5 kg to < 20 kg, who received at least one dose of study drug (paediatric safety population). PA was administered once daily for 3 days; two trials included the comparator artemether-lumefantrine (AL). PCR-adjusted day 28 adequate clinical and parasitological response (ACPR) was evaluated. Real-world PA granules safety and effectiveness was also considered. In the integrated safety analysis, 63.9% (95% CI 60.2, 67.4; 426/667) of patients had adverse events following PA and 62.0% (95% CI 56.9, 66.9; 222/358) with AL. Vomiting was more common with PA (7.8% [95% CI 6.0, 10.1; 52/667]) than AL (3.4% [95% CI 1.9, 5.8; 12/358]), relative risk 2.3 (95% CI 1.3, 4.3; P = 0.004), occurring mainly following the first PA dose (6.7%, 45/667), without affecting re-dosing or adherence. Prolonged QT interval occurred less frequently with PA (3.1% [95% CI 2.1, 4.8; 21/667]) than AL (8.1% [95% CI 5.7, 11.4; 29/358]), relative risk 0.39 (95% CI 0.22, 0.67; P = 0.0007). In CANTAM, adverse events were reported for 17.7% (95% CI 16.3, 19.2; 460/2599) of patients, most commonly vomiting (5.4% [95% CI 4.6, 6.4; 141/2599]), mainly following the first dose, (4.5% [117/2599]), with all patients successfully re-dosed, and pyrexia (5.4% [95% CI 4.6, 6.3; 140/2599]). In the two comparative clinical trials, Day 28 ACPR in the per-protocol population for PA was 97.1% (95% CI 94.6, 98.6; 329/339) and 100% (95% CI 99.3, 100; 514/514) versus 98.8% (95% CI 95.7, 99.9; 165/167) and 98.4% (95% CI 95.5, 99.7; 188/191) for AL, respectively. In CANTAM, PA clinical effectiveness was 98.0% (95% CI 97.3, 98.5; 2273/2320). Anti-malarial treatment with PA paediatric granules administered once daily for 3 days was well tolerated in children and displayed good clinical efficacy in clinical trials, with effectiveness confirmed in a real-world study. Trial registration Clinicaltrials.gov: SP-C-003-05: identifier NCT00331136; SP-C-007-07: identifier NCT0541385; SP-C-021-15: identifier NCT03201770. Pan African Clinical Trials Registry: SP-C-013-11: identifier PACTR201105000286876.
Sections du résumé
BACKGROUND
BACKGROUND
Children are particularly at risk of malaria. This analysis consolidates the clinical data for pyronaridine-artesunate (PA) paediatric granules in children from three randomized clinical trials and a real-world study (CANTAM).
METHODS
METHODS
An integrated safety analysis of individual patient data from three randomized clinical trials included patients with microscopically-confirmed Plasmodium falciparum, body weight ≥ 5 kg to < 20 kg, who received at least one dose of study drug (paediatric safety population). PA was administered once daily for 3 days; two trials included the comparator artemether-lumefantrine (AL). PCR-adjusted day 28 adequate clinical and parasitological response (ACPR) was evaluated. Real-world PA granules safety and effectiveness was also considered.
RESULTS
RESULTS
In the integrated safety analysis, 63.9% (95% CI 60.2, 67.4; 426/667) of patients had adverse events following PA and 62.0% (95% CI 56.9, 66.9; 222/358) with AL. Vomiting was more common with PA (7.8% [95% CI 6.0, 10.1; 52/667]) than AL (3.4% [95% CI 1.9, 5.8; 12/358]), relative risk 2.3 (95% CI 1.3, 4.3; P = 0.004), occurring mainly following the first PA dose (6.7%, 45/667), without affecting re-dosing or adherence. Prolonged QT interval occurred less frequently with PA (3.1% [95% CI 2.1, 4.8; 21/667]) than AL (8.1% [95% CI 5.7, 11.4; 29/358]), relative risk 0.39 (95% CI 0.22, 0.67; P = 0.0007). In CANTAM, adverse events were reported for 17.7% (95% CI 16.3, 19.2; 460/2599) of patients, most commonly vomiting (5.4% [95% CI 4.6, 6.4; 141/2599]), mainly following the first dose, (4.5% [117/2599]), with all patients successfully re-dosed, and pyrexia (5.4% [95% CI 4.6, 6.3; 140/2599]). In the two comparative clinical trials, Day 28 ACPR in the per-protocol population for PA was 97.1% (95% CI 94.6, 98.6; 329/339) and 100% (95% CI 99.3, 100; 514/514) versus 98.8% (95% CI 95.7, 99.9; 165/167) and 98.4% (95% CI 95.5, 99.7; 188/191) for AL, respectively. In CANTAM, PA clinical effectiveness was 98.0% (95% CI 97.3, 98.5; 2273/2320).
CONCLUSIONS
CONCLUSIONS
Anti-malarial treatment with PA paediatric granules administered once daily for 3 days was well tolerated in children and displayed good clinical efficacy in clinical trials, with effectiveness confirmed in a real-world study. Trial registration Clinicaltrials.gov: SP-C-003-05: identifier NCT00331136; SP-C-007-07: identifier NCT0541385; SP-C-021-15: identifier NCT03201770. Pan African Clinical Trials Registry: SP-C-013-11: identifier PACTR201105000286876.
Identifiants
pubmed: 38418982
doi: 10.1186/s12936-024-04885-3
pii: 10.1186/s12936-024-04885-3
doi:
Banques de données
ClinicalTrials.gov
['NCT00331136', 'NCT0541385', 'NCT03201770']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
61Informations de copyright
© 2024. The Author(s).
Références
WHO. World malaria report. Geneva: World Health Organization; 2023. https://www.who.int/publications/i/item/9789240086173 . Accessed 12 Dec 2023.
Cohee LM, Opondo C, Clarke SE, Halliday KE, Cano J, Shipper AG, et al. Preventive malaria treatment among school-aged children in sub-Saharan Africa: a systematic review and meta-analyses. Lancet Glob Health. 2020;8:e1499–511.
doi: 10.1016/S2214-109X(20)30325-9
pubmed: 33222799
pmcid: 7721819
Oshagbemi OA, Lopez-Romero P, Winnips C, Csermak KR, Su G, Aubrun E. Estimated distribution of malaria cases among children in sub-Saharan Africa by specified age categories using data from the Global Burden of Diseases 2019. Malar J. 2023;22:371.
doi: 10.1186/s12936-023-04811-z
pubmed: 38053100
pmcid: 10696666
Kurth F, Belard S, Adegnika AA, Gaye O, Kremsner PG, Ramharter M. Do paediatric drug formulations of artemisinin combination therapies improve the treatment of children with malaria? A systematic review and meta-analysis. Lancet Infect Dis. 2010;10:125–32.
doi: 10.1016/S1473-3099(09)70327-5
pubmed: 20113981
WHO. Guidelines for malaria. Geneva: World Health Organization; 2022. https://www.who.int/publications/i/item/guidelines-for-malaria . Accessed 28 Feb 2023.
Tshefu AK, Gaye O, Kayentao K, Thompson R, Bhatt KM, Sesay SS, et al. Efficacy and safety of a fixed-dose oral combination of Pyronaridine–artesunate compared with artemether–lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet. 2010;375:1457–67.
doi: 10.1016/S0140-6736(10)60322-4
pubmed: 20417857
Poravuth Y, Socheat D, Rueangweerayut R, Uthaisin C, Pyae Phyo A, Valecha N, et al. Pyronaridine–artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. PLoS ONE. 2011;6: e14501.
doi: 10.1371/journal.pone.0014501
pubmed: 21267072
pmcid: 3022577
Rueangweerayut R, Phyo AP, Uthaisin C, Poravuth Y, Binh TQ, Tinto H, et al. Pyronaridine–artesunate versus mefloquine plus artesunate for malaria. N Engl J Med. 2012;366:1298–309.
doi: 10.1056/NEJMoa1007125
pubmed: 22475593
Duparc S, Borghini-Fuhrer I, Craft CJ, Arbe-Barnes S, Miller RM, Shin CS, et al. Safety and efficacy of pyronaridine–artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials. Malar J. 2013;12:70.
doi: 10.1186/1475-2875-12-70
pubmed: 23433102
pmcid: 3598551
Ramharter M, Kurth F, Schreier AC, Nemeth J, Glasenapp I, Belard S, et al. Fixed-dose pyronaridine–artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J Infect Dis. 2008;198:911–9.
doi: 10.1086/591096
pubmed: 18694333
Kayentao K, Doumbo OK, Penali LK, Offianan AT, Bhatt KM, Kimani J, et al. Pyronaridine–artesunate granules versus artemether–lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial. Malar J. 2012;11:364.
doi: 10.1186/1475-2875-11-364
pubmed: 23113947
pmcid: 3566922
West African Network for Clinical Trials of Antimalarial Drugs. Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. Lancet. 2018;391:1378–90.
doi: 10.1016/S0140-6736(18)30291-5
Sagara I, Beavogui AH, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, et al. Safety and efficacy of re-treatments with pyronaridine–artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. Lancet Infect Dis. 2016;16:189–98.
doi: 10.1016/S1473-3099(15)00318-7
pubmed: 26601738
pmcid: 4726763
Roth JM, Sawa P, Makio N, Omweri G, Osoti V, Okach S, et al. Pyronaridine–artesunate and artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial. Malar J. 2018;17:199.
doi: 10.1186/s12936-018-2340-3
pubmed: 29764419
pmcid: 5952621
Tona Lutete G, Mombo-Ngoma G, Assi SB, Bigoga JD, Koukouikila-Koussounda F, Ntamabyaliro NY, et al. Pyronaridine–artesunate real-world safety, tolerability, and effectiveness in malaria patients in 5 African countries: a single-arm, open-label, cohort event monitoring study. PLoS Med. 2021;18: e1003669.
doi: 10.1371/journal.pmed.1003669
pubmed: 34129601
pmcid: 8205155
Ayyoub A, Methaneethorn J, Ramharter M, Djimde AA, Tekete M, Duparc S, et al. Population pharmacokinetics of pyronaridine in pediatric malaria patients. Antimicrob Agents Chemother. 2015;60:1450–8.
doi: 10.1128/AAC.02004-15
pubmed: 26666916
European Medicines Agency. Pyramax: opinion on medicine for use outside EU. Amsterdam: EMA; 2016. https://www.ema.europa.eu/en/opinion-medicine-use-outside-EU/human/pyramax . Accessed 14 Mar 2022.
WHO. Methods of surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009. https://apps.who.int/iris/handle/10665/44048 . Accessed 14 Mar 2022.
WHO. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. Geneva: World Health Organization; 2008. https://www.who.int/publications/i/item/9789241596305 . Accessed 16 Mar 2022.
Assefa DG, Zeleke ED, Molla W, Mengistu N, Sefa A, Mebratu A, et al. Safety of dihydroartemisinin–piperaquine versus artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria among children in Africa: a systematic review and meta-analysis of randomized control trials. Malar J. 2022;21:4.
doi: 10.1186/s12936-021-04032-2
pubmed: 34983552
pmcid: 8725395
Pryce J, Hine P. Pyronaridine–artesunate for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev. 2019;1:CD006404.
pubmed: 30620055